Why Are Drugs More Profitable Than Vaccines?
Year of publication: |
July 2003
|
---|---|
Authors: | Kremer, Michael |
Other Persons: | Snyder, Christopher M. (contributor) |
Institutions: | National Bureau of Economic Research (contributor) |
Publisher: |
Cambridge, Mass : National Bureau of Economic Research |
Subject: | Arzneimittel | Pharmaceuticals | Impfung | Vaccination | Pharmakologie | Pharmacology | Rentabilität | Profitability |
Extent: | 1 Online-Ressource |
---|---|
Series: | NBER working paper series ; no. w9833 |
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Mode of access: World Wide Web System requirements: Adobe [Acrobat] Reader required for PDF files Hardcopy version available to institutional subscribers. |
Other identifiers: | 10.3386/w9833 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
When is prevention more profitable than cure? : the impact of time-varying consumer heterogeneity
Kremer, Michael, (2013)
-
When is prevention more profitable than cure? : the impact of time-varying consumer heterogeneity
Kremer, Michael, (2013)
-
When is prevention more profitable than cure? : the impact of time-varying consumer heterogeneity
Kremer, Michael, (2013)
- More ...
-
Testing Fractional doses of COVID-19 Vaccines
Więcek, Witold, (2021)
-
Could Vaccine Dose Stretching Reduce COVID-19 Deaths?
Wiecek, Witold, (2021)
-
Advance Market Commitments : Insights from Theory and Experience
Kremer, Michael, (2020)
- More ...